The Categorisation Commission for Medicinal Products approved at the August meeting other modern medicines, which will be reimbursed for Slovak patients. As from 1 November 2024, Sibnayal, Fintepa and Zynlonta will be added to the list of categorised medicines and Leqvio will be extended to include other diseases.
One of the medicines that will be covered by health insurance from December onwards is Fintepa with the active substance fenfluramine. It is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as adjunctive therapy to other antiepileptics for patients aged 2 years and older. Patients are given as a solution. – In these diseases, the quality of life is reduced not only for patients, but also for their families or carers. There is a need for constant patient monitoring, which requires a constant presence of a parent; Minister for Health Zuzana Dolinková explained. As reported by studies and current available clinical data, the drug not only reduces the number of seizures, but also positively affects cognitive function and improves quality of life.
Other medicinal products classified as "categorised':SibnayalMedicinal product with the active substance potassium citrate and potassium bicarbonate. Indication: Treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children from one year of age. It is administered orally as prolonged-release granules.ZynlontaMedicinal product with the active substance loncastuximab-tesirine. Indication: Treatment of adult patients with relapsed or refractory diffuse large B-lymphoma (DLBCL) and highly malignant B-lymphoma (HGBL) after two or more lines of systemic treatment. It is given intravenously as an infusion.Leqvio – Extended indicationMedicinal product with the active substance Inklisiran. Indication: Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet, in combination with a statin or other lipid-lowering therapy.
For more information on medicinal products, see the website of the State Institute for Drug Control: https://www.sukl.sk/.